United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Research Report Forecast 2017-2021

March 2017 | 133 pages | ID: UBE617A968EEN
S&P Consulting

Abstracts

The United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the Non-alcoholic Fatty Liver Disease (NAFLD) Drug industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Non-alcoholic Fatty Liver Disease (NAFLD) Drug market study provides comprehensive data which enhances the understanding, scope and application of this report.

This report provides comprehensive analysis of

• Key market segments and sub-segments
• Evolving market trends and dynamics
• Changing supply and demand scenarios
• Quantifying market opportunities through market sizing and market forecasting
• Tracking current trends/opportunities/challenges
• Competitive insights
• Opportunity mapping in terms of technological breakthroughs

The Major players reported in the market include:

Conatus Pharmaceuticals
Daewoong Pharmaceutical
Galmed International
Kyorin Pharmaceutical
Metabolic Solutions Development
Novartis AG
Phenex Pharmaceuticals
Raptor Pharmaceuticals
TCM Biotech International

United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market: Product Segment Analysis

Type 1
Type 2
Type 3

United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market: Application Segment Analysis

Application 1
Application 2
Application 3

Reasons for Buying this Report

• This report provides pin-point analysis for changing competitive dynamics
• It provides a forward looking perspective on different factors driving or restraining market growth
• It provides a six-year forecast assessed on the basis of how the market is predicted to grow
• It helps in understanding the key product segments and their future
• It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
• It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Contents

United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Research Report Forecast 2017-2021

CHAPTER 1 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MARKET OVERVIEW

1.1 Product Overview and Scope of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
1.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Segmentation by Type
  1.2.1 United States Production Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Type in 2015
  1.2.1 Type
  1.2.2 Type
  1.2.3 Type
1.3 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Segmentation by Application
  1.3.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Market Share by Application in 2015
  1.3.2 Application
  1.3.3 Application
  1.3.4 Application
1.4 United States Market Size Sales (Value) and Revenue (Volume) of Non-alcoholic Fatty Liver Disease (NAFLD) Drug (2011-2021)

CHAPTER 2 UNITED STATES ECONOMIC IMPACT ON NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG INDUSTRY

2.1 United States Macroeconomic Analysis
2.2 United States Macroeconomic Environment Development Trend

CHAPTER 3 UNITED STATES NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MARKET COMPETITION BY MANUFACTURERS

3.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production and Share by Manufacturers (2015 and 2016)
3.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Share by Manufacturers (2015 and 2016)
3.3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Average Price by Manufacturers (2015 and 2016)
3.4 Manufacturers Non-alcoholic Fatty Liver Disease (NAFLD) Drug Manufacturing Base Distribution, Production Area and Product Type
3.5 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Competitive Situation and Trends
  3.5.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Concentration Rate
  3.5.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share of Top 3 and Top 5 Manufacturers
  3.5.3 Mergers & Acquisitions, Expansion

CHAPTER 4 UNITED STATES NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG PRODUCTION, REVENUE (VALUE), PRICE TREND BY TYPE

4.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production and Market Share by Type (2012-2017)
4.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Market Share by Type (2012-2017)
4.3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Price by Type (2012-2017)
4.4 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production Growth by Type (2012-2017)

CHAPTER 5 UNITED STATES NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MARKET ANALYSIS BY APPLICATION

5.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption and Market Share by Application (2012-2017)
5.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities
  5.3.1 Potential Applications
  5.3.2 Emerging Markets/Countries

CHAPTER 6 UNITED STATES NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MANUFACTURERS ANALYSIS

6.1 Conatus Pharmaceuticals
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Product Type, Application and Specification
  6.1.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Business Overview
6.2 Daewoong Pharmaceutical
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Product Type, Application and Specification
  6.2.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Business Overview
6.3 Galmed International
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Product Type, Application and Specification
  6.3.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Business Overview
6.4 Kyorin Pharmaceutical
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Product Type, Application and Specification
  6.4.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Business Overview
6.5 Metabolic Solutions Development
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Product Type, Application and Specification
  6.5.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Business Overview
6.6 Novartis AG
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Product Type, Application and Specification
  6.6.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Business Overview
6.7 Phenex Pharmaceuticals
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Product Type, Application and Specification
  6.7.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Business Overview
6.8 Raptor Pharmaceuticals
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Product Type, Application and Specification
  6.6.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Business Overview
6.9 TCM Biotech International
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Product Type, Application and Specification
  6.9.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Business Overview

CHAPTER 7 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MANUFACTURING COST ANALYSIS

7.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

CHAPTER 8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Non-alcoholic Fatty Liver Disease (NAFLD) Drug Major Manufacturers in 2015
8.4 Downstream Buyers

CHAPTER 9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

CHAPTER 10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

CHAPTER 11 UNITED STATES NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MARKET FORECAST (2017-2021)

11.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue Forecast (2017-2021)
11.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Consumption Forecast by Regions (2017-2021)
11.3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production Forecast by Type (2017-2021)
11.4 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast by Application (2017-2021)
11.5 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Price Forecast (2017-2021)

CHAPTER 12 APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Table Classification of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Figure United States Sales Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Type in 2015
Table Application of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Figure United States Sales Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Application in 2015
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2011-2021)
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2011-2021)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales of Key Manufacturers (2015 and 2016)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Manufacturers
Figure 2016 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Manufacturers
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue by Manufacturers (2015 and 2016)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Manufacturers
Table 2016 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Manufacturers
Table United States Market Non-alcoholic Fatty Liver Disease (NAFLD) Drug Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market Non-alcoholic Fatty Liver Disease (NAFLD) Drug Average Price of Key Manufacturers in 2015
Figure Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share of Top 3 Manufacturers
Figure Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share of Top 5 Manufacturers
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Type (2012-2017)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Type (2012-2017)
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share by Type in 2015
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Market Share by Type (2012-2017)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Type (2012-2017)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Price by Type (2012-2017)
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Growth Rate by Type (2012-2017)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Application (2012-2017)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share by Application (2012-2017)
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share by Application in 2015
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Growth Rate by Application (2012-2017)
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Growth Rate by Application (2012-2017)
Table Conatus Pharmaceuticals Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Conatus Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)
Table Conatus Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)
Table Daewoong Pharmaceutical Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Daewoong Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)
Table Daewoong Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)
Table Galmed International Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Galmed International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)
Table Galmed International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)
Table Kyorin Pharmaceutical Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Kyorin Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)
Table Kyorin Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)
Table Metabolic Solutions Development Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Metabolic Solutions Development Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)
Table Metabolic Solutions Development Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)
Table Novartis AG Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Novartis AG Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)
Table Novartis AG Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)
Table Phenex Pharmaceuticals Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Phenex Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)
Table Phenex Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)
Table Raptor Pharmaceuticals Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Raptor Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)
Table Raptor Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)
Table TCM Biotech International Basic Information, Manufacturing Base, Production Area and Its Competitors
Table TCM Biotech International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)
Table TCM Biotech International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Figure Manufacturing Process Analysis of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Figure Non-alcoholic Fatty Liver Disease (NAFLD) Drug Industrial Chain Analysis
Table Raw Materials Sources of Non-alcoholic Fatty Liver Disease (NAFLD) Drug Major Manufacturers in 2015
Table Major Buyers of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Table Distributors/Traders List
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production and Growth Rate Forecast (2017-2021)
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate Forecast (2017-2021)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production Forecast by Type (2017-2021)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast by Application (2017-2021)

COMPANIES MENTIONED

Conatus Pharmaceuticals, Daewoong Pharmaceutical, Galmed International, Kyorin Pharmaceutical, Metabolic Solutions Development, Novartis AG, Phenex Pharmaceuticals, Raptor Pharmaceuticals, TCM Biotech International, Tobira Therapeutics, Verva Pharmaceuticals, Zafgen